Drug intelligence / Profile preview

HRG2010(I)

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**HRG2010(I)** is an investigational HRG2010 formulation variant developed by Jiangsu Hengrui Pharmaceuticals for Parkinson's disease with motor fluctuations. It was evaluated as a distinct treatment intervention in the completed HRG2010-201 Phase II trial, which compared HRG2010(I) and HRG2010(II) with sustained-release carbidopa/levodopa. Public trial materials do not disclose the exact active-ingredient composition, release characteristics, dosage form, or molecular mechanism specific to the HRG2010(I) variant. ([ctv.veeva.com](https://ctv.veeva.com/study/pharmacokineticspharmacodynamicsefficacy-and-safety-of-hrg2010-in-parkinsons-disease-patients-wit))

Other names: HRG2010 (I)

Targets

DDC (Aromatic L-amino acid decarboxylase)

Beyond the preview

Go deeper on HRG2010(I).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRG2010(I).

Explore the full profile